围术期经皮穴位电刺激对体外循环冠脉搭桥患者单核细胞HLA-DR表达的影响:双盲随机对照试验研究方案
本研究为单中心双盲随机对照试验方案,计划纳入88例择期体外循环下冠状动脉旁路移植术患者,随机分为经皮穴位电刺激(TEAS)组与假TEAS组。主要终点为术后单核细胞HLA-DR表达,次要终点包括IL-6、IL-10及感染并发症、ICU停留时间和死亡率等。研究旨在初步探讨围术期TEAS能否逆转搭桥相关免疫抑制。
要点
- 围术期TEAS为无创技术,可能改善体外循环心脏术后免疫抑制。
- 主要终点为单核细胞HLA-DR表达,属非临床终点。
- 结果为后续以患者为中心临床结局的大型试验提供依据。
核心结论
- 围术期TEAS能否改善体外循环冠脉搭桥术后免疫抑制尚不明确,本方案旨在初步评估其对该人群单核细胞HLA-DR表达的影响。
研究设计与样本
- 单中心双盲随机对照试验方案,计划将88例择期体外循环下冠状动脉旁路移植术患者随机分为TEAS组与假TEAS组。
主要发现
- 原文为研究方案,未报告研究结果。
关键数值与推荐
- 主要终点为单核细胞HLA-DR表达。
- 次要终点包括IL-6、IL-10等实验室参数及术后感染并发症、ICU停留时间和死亡率等临床结局。
- 另将检测高迁移率族蛋白B1和调节性T细胞等免疫指标。
临床怎么用
- 目前尚不能据此方案改变临床实践,需等待试验结果。
局限性
- 本研究为初步单中心临床试验,主要终点为非临床指标,直接临床影响有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac surgery involving cardiopulmonary bypass (CPB) is known to be associated with a transient postoperative immunosuppression. When severe and persistent, this immune dysfunction predisposes patients to infectious complications, which contributes to a prolonged stay in the intensive care unit (ICU), and even mortality. Effective prevention and treatment methods are still lacking. Recent studies revealed that acupuncture-related techniques, such as electroacupuncture and transcutaneous electrical acupoint stimulation (TEAS), are able to produce effective cardioprotection and immunomodulation in adult and pediatric patients undergoing cardiac surgery with CPB, which leads to enhanced recovery. However, whether perioperative application of TEAS, a non-invasive technique, is able to improve immunosuppression of the patients with post-cardiosurgical conditions is unknown. Thus, as a preliminary study, the main objective is to evaluate the effects of TEAS on the postoperative expression of monocytic human leukocyte antigen (-D related) (mHLA-DR), a standardized "global" biomarker of injury or sepsis-associated immunosuppression, in patients receiving on-pump coronary artery bypass grafting (CABG). METHODS: This study is a single-center clinical trial. The 88 patients scheduled to receive CABG under CPB will be randomized into two groups: the group receiving TEAS, and the group receiving transcutaneous acupoint pseudo-electric stimulation (Sham TEAS). Expression of mHLA-DR serves as a primary endpoint, and other laboratory parameters (e.g., interleukin [IL]-6, IL-10) and clinical outcomes (e.g., postoperative infectious complications, ICU stay time, and mortality) as the secondary endpoints. In addition, immune indicators, such as high mobility group box 1 protein and regulatory T cells will also be measured. DISCUSSION: The current study is a preliminary monocentric clinical trial with a non-clinical primary endpoint, expression of mHLA-DR, aiming at determining whether perioperative application of TEAS has a potential to reverse CABG-associated immunosuppression. Although the immediate clinical impact of this study is limited, its results would inform further large-sample clinical trials using relevant patient-centered clinical outcomes as primary endpoints. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02933996. Registered on 13 October 2016.
引用
- Chen WT, Wei JF, Wang L, et al. Effects of perioperative transcutaneous electrical acupoint stimulation on monocytic HLA-DR expression in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass: study protocol for a double-blind randomized controlled trial. Trials. 2019. PMID: 31888744. doi:10.1186/s13063-019-3889-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。